CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access
At-Home Option An Important Growth Driver for Eisai/Biogen
The first results for subcutaneous lecanemab in early Alzheimer’s disease show better amyloid clearance with slightly higher ARIA rates than the I.V. version. Eisai also presented Phase III Clarity AD updates and initial long-term extension data.
